|By PR Newswire||
|April 12, 2014 09:00 AM EDT||
LONDON, April 12, 2014 /PRNewswire/ --
Emerging biological drugs - discover R&D, business analysis, and revenue forecasts
What's the future of biologics, especially new drug classes? Now get the latest technological and commercial analysis. Staying ahead in data and knowledge, you benefit your authority. And you explore trends, developments, results, opportunities, and sales predictions.
So visiongain's new report shows you what's possible for biological drugs - their next phase. There avoid missing out. Instead find progress in that industry and market, discovering expected progress and revenues. See now how you can gain.
New biotechnological medicines will benefit patients and pharmaceutical companies. Read on to explore those therapies, hearing how high revenues can go.
Forecasting and other information showing the most lucrative possibilities for treatments
That study gives you sales forecasts to 2024 at overall world, submarket, product, and national level. See what the future holds, assessing gains for developers and producers.
Many opportunities exist. And besides giving revenue predictions, that new analysis shows recent results, growth rates, and market shares. There you discover 94 tables, 55 charts, and two interviews with authorities in the biopharmaceuticals sector.
And the following sections explain what our new investigation gives you.
Analyses exclusive to that study, showing the most important commercial potentials
In our report you get data found nowhere else. Discover what's really going on. Our forecasting system goes to the core of the biopharmaceutical industry's sales potential like no other work, giving revenue predictions and their meanings.
That analysis benefits your plans, decisions, and influence by interpreting medical needs, R&D, and companies' abilities. You hear what's happening, then, assessing likely gains.
So find in those analyses where potential and money lie, also saving time, worry, and effort.
Prospects for the world market and submarkets - what's possible for pharma biotechnology?
There, in our report, discover overall world sales to 2024 for biologics and new therapies, with discussions.
Also get individual revenue predictions to 2024 for 17 next-generation biologic submarkets at world level:
• Regenerative medicine, with submarket breakdowns for tissue engineering, stem cells, and gene therapies
• Antibodies, including monoclonal antibodies (mAbs), with sub-forecasting for antibody-drug conjugates (ADCs), engineered, and bispecific agents
• Antibody fragments and antibody-like protein (ALP) platforms
• Biosimilars (follow-on protein products).
To see a report overview please email Sara Peerun on [email protected]
And discover other segments' forecasts to 2024:
• Insulins, with submarkets for ultra-long acting, oral, and ultra-rapid-acting insulins
• Growth hormones
• Recombinant coagulation factors
• Other types of next-stage therapeutic proteins.
Next-generation biologics that treat new indications will be launched within 10 years. And you assess outlooks for that expansion in trade, hearing where you could gain.
Our study also explores competition. There you see what's happening for developers, producers, and sellers of new-generation biologics, understanding challenges, trends, and outlooks.
That work also splits its overall world market into leading products, showing where you could profit from new and improved biotech medicines.
Product forecasts for new forms, variations, and uses of biological therapy
How will individual drugs perform to 2024 at world level? Our report predicts revenues of seven top brands:
There you find products and years with highest forecasted sales. And the report predicts those seven therapies will earn combined revenue of more than $10bn in 2024.
You also examine competitors. See what's happening, then, understanding challenges, trends, competition, and opportunities. And here's what that study's author said:
"Next-generation biologics will address shortcomings in current therapies, including inconvenient dosing and concerns over side effects. Developmental trends include sustained release, for less-frequent dosing, and reformulations for oral and topical administration."
That work also gives geographical revenue forecasts.
Healthcare in national markets - what outlooks for business in new biopharma products?
Advances in biotechnology and healthcare expand use of novel biological drugs in developed and developing countries. Also opportunities exist for newer treatments.
And our analyses show you individual revenue forecasts to 2024 for nine national markets:
• United States (US)
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
There you hear about the best sales potentials, appraising national opportunities for next-generation biologicals. See where and how you can profit.
For treating people and saving lives, you explore progress, needs, and possibilities. Find how pharma companies satisfy those demands, also assessing expected financial gains.
And what events influence the biologics industry? What's the outlook for tackling serious diseases? Our work shows you, discussing trends, challenges, and opportunities.
Market forces and issues - what affects biopharma developers, producers, and sellers?
The report explains trends, processes, and events affecting the biopharma industry and market from 2014, including these forces:
• Limitations of existing biologics
• Promise of next-generation biologics, and product launches
• Extension of half-life - pegylation and other technologies
• Demand rising for biological therapies
• Contract manufacturers (CMOs) serving those developmental needs and trends.
To see a report overview please email Sara Peerun on [email protected]
And you explore these influences, among others:
• Disease incidence affecting demand for those more-developed medicines
• Improvements in therapeutic antibodies, including targeted cytotoxic therapies
• R&D pipelines - e.g. for immunotoxins - including agents in clinical development
• Biosimilar insulins likely from 2015 - transformation of that market
• Effects of rising incidence rates in cancer, diabetes, and cardiovascular disorders.
There discover what the future holds. You explore political, economic, social, and technological questions. See too how R&D helps companies benefit patients.
So you explore what progress, trends, and prospects mean. And discover what helps and what hinders players in that healthcare industry, affecting participants' results.
Biological drug technology and applications - companies and 2018 market value
So what happens next? From 2014, novel and biosimilar treatments will benefit patients, doctors, and payers. Those advances will encourage investments, medical progress, and higher revenues from more-advanced biological drugs.
And our study predicts the next-generation biologics market will reach $12.17bn worldwide in 2018, and then multiply in revenues to 2024. See what's possible and what you can gain.
That work also explores activities of these leading companies, among many other firms:
• Eli Lilly
• Novo Nordisk
• Kyowa Hakko Kirin
• Baxter International.
In that market, large pharmaceutical corporations and smaller biopharma specialists can win. See how.
And you find 235 organisations covered. You also get interviews with two companies in the industry, helping you stay ahead. See, then, what the future holds.
Ways Next-Generation Biologics: R&D, Industry and Market 2014-2024 helps
In three main ways our new investigation helps you gain recognition for insight, with data found only there:
• Revenues to 2024 at world level, for 17 submarkets, and 7 products - explore outlooks for production, marketing, and sales
• Forecasts to 2024 for 9 national markets in North America, Europe, and Asia - assess countries for revenues and sales expansions
• Prospects for established competitors, rising companies, and new entrants - investigate portfolios, results, strategies, R&D, and opinions from interviews.
Knowledge there found nowhere else, helping your searches, analyses, and planning
Our new report provides competitive intelligence, showing where progress and money lie.
That work's purpose is to predict sales results with maximum clarity, applicability, and detail. And its research and analyses identify and explain commercial prospects. Now you explore the biological drug industry's future through data exclusive to that study.
So our analysis helps you avoid falling behind in information or missing opportunity. Also it lets you save time and effort. And now your choice could benefit your plans, decisions, and authority - increasing your chances of finding competitive advantages.
Biopharmaceutical knowledge - getting our new report now helps you stay ahead
By trying our new study on emerging biologicals you explore trends, R&D, and sales predictions. There stay ahead - please get that report here now.
To request a report overview please email Sara Peerun at [email protected] or call Tel : +44 (0) 20 7336 6100
Companies Listed in this report:
Adnexus (part of Bristol-Myers Squibb)
Advanced Cell Technology
Agence Nationale de sécurité du Médicament et des produits de santé (ANSM)
Alcon (part of Novartis)
Alfacell (now Tamir Biotechnology)
Applied Genetic Technologies (AGTC)
Biopartners (part of Bioton)
BioVex Group (part of Amgen)
BioWa (part of Kyowa Hakko Kirin)
BrainStorm Cell Therapeutics
Catalent Pharma Solutions
Cellular Dynamics International (CDI)
Centers for Disease Prevention and Control (CDC) [US]
Cephalon (part of Teva)
CEPiA (part of Sanofi)
Children's Hospital of Philadelphia (CHOP)
China Food and Drug Administration (CFDA)
Chugai (part of Roche)
Depuy Mitek (part of J&J)
Dr. Reddy's Laboratories
Duke University Hospital
Elan Pharmaceuticals (now part of Perrigo Company)
EMA's Committee for Medicinal Products for Human Use (CHMP)
Epitomics (part of Abcam)
ESBATech (part of Novartis)
European Medicines Agency (EMA)
Food and Drug Administration (FDA) [US]
Fresenius Biotech (now named Neovii Biotech, part of Neopharm)
Fujifilm Diosynth Biotechnologies
Genentech (part of Roche)
Genzyme (part of Sanofi)
Human Stem Cells Institute (HSCI)
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
International Diabetes Federation (IDF)
Kyowa Hakko Kirin
LG Life Sciences
MedImmune (part of AstraZeneca)
Merck & Co.
Micromet (part of Amgen)
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
Moorfields Eye Hospital [UK]
National Cancer Institute (NCI) [US]
National Health Service (NHS) [UK]
National Institute for Health and Care Excellence (NICE) [UK]
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [US]
Prolor Biotech (part of OPKO Health)
ratiopharm (part of Teva)
Reliance Life Sciences
Roche Glycart (part of Roche)
Royal Institute of Technology [Sweden]
Russian Ministry of Healthcare (Minzdrav)
Sandoz (part of Novartis)
Scottish Medicines Consortium (SMC)
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech (part of Benda)
Shreya Life Sciences
Spirogen (part of AstraZeneca)
Stelis Biopharmaceuticals (part of Strides Arcolab)
Swedish Orphan Biovitrum (Sobi)
Swiss Federal Institute of Technology
Synthon Biopharmaceuticals (part of Synthon)
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
Tianjin International Joint Academy of Bio-medicine
University of Toronto
University of California, San Francisco (UCSF)
World Bank Group
World Cancer Research Fund (WCRF)
World Health Organization (WHO)
Wyeth (part of Pfizer)
Yale School of Medicine
To see a report overview please email Sara Peerun on [email protected]
SYS-CON Events announced today that Dataloop.IO, an innovator in cloud IT-monitoring whose products help organizations save time and money, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Dataloop.IO is an emerging software company on the cutting edge of major IT-infrastructure trends including cloud computing and microservices. The company, founded in the UK but now based in San Fran...
Jan. 24, 2017 04:15 PM EST Reads: 2,726
"There's a growing demand from users for things to be faster. When you think about all the transactions or interactions users will have with your product and everything that is between those transactions and interactions - what drives us at Catchpoint Systems is the idea to measure that and to analyze it," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York Ci...
Jan. 24, 2017 02:30 PM EST Reads: 5,917
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Jan. 24, 2017 02:30 PM EST Reads: 5,391
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
Jan. 24, 2017 02:15 PM EST Reads: 3,274
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
Jan. 24, 2017 01:45 PM EST Reads: 3,018
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Jan. 24, 2017 01:30 PM EST Reads: 4,497
Discover top technologies and tools all under one roof at April 24–28, 2017, at the Westin San Diego in San Diego, CA. Explore the Mobile Dev + Test and IoT Dev + Test Expo and enjoy all of these unique opportunities: The latest solutions, technologies, and tools in mobile or IoT software development and testing. Meet one-on-one with representatives from some of today's most innovative organizations
Jan. 24, 2017 01:00 PM EST Reads: 1,738
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in Embedded and IoT solutions, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 7-9, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/Big Data, HPC and E...
Jan. 24, 2017 12:45 PM EST Reads: 5,929
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
Jan. 24, 2017 12:30 PM EST Reads: 3,738
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed ...
Jan. 24, 2017 12:15 PM EST Reads: 6,531
“DevOps is really about the business. The business is under pressure today, competitively in the marketplace to respond to the expectations of the customer. The business is driving IT and the problem is that IT isn't responding fast enough," explained Mark Levy, Senior Product Marketing Manager at Serena Software, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Jan. 24, 2017 12:15 PM EST Reads: 11,744
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smart...
Jan. 24, 2017 12:00 PM EST Reads: 2,876
The WebRTC Summit New York, to be held June 6-8, 2017, at the Javits Center in New York City, NY, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 20th International Cloud Expo and @ThingsExpo. WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web co...
Jan. 24, 2017 11:45 AM EST Reads: 3,076
"A lot of times people will come to us and have a very diverse set of requirements or very customized need and we'll help them to implement it in a fashion that you can't just buy off of the shelf," explained Nick Rose, CTO of Enzu, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jan. 24, 2017 10:45 AM EST Reads: 4,836
Buzzword alert: Microservices and IoT at a DevOps conference? What could possibly go wrong? In this Power Panel at DevOps Summit, moderated by Jason Bloomberg, the leading expert on architecting agility for the enterprise and president of Intellyx, panelists peeled away the buzz and discuss the important architectural principles behind implementing IoT solutions for the enterprise. As remote IoT devices and sensors become increasingly intelligent, they become part of our distributed cloud enviro...
Jan. 24, 2017 08:45 AM EST Reads: 5,101